Uscom Limited · ASX:UCM
Uscom — Shareholder Meeting (2017)
32 slides from Uscom's shareholder meeting presentation, 2017
Slide 1: Uscom
= Uscom “Never has scale been more important for the success and growth of a global business!”
Slide 2: Uscom AGM17
Uscom AGM17
Slide 3: Agenda
QUORUM @ Yam WELCOME CHARIMAN’S REPORT (ij Ua RESULTS STRATEGY 18 @ fom NOTICE OF MEETING CONSIDERATION OF REPORTS @% [ay BUSINESS - RESOLUTIONS 1 - 6 CLOSE OF MEETING @@ Efe) QUESTION TIME
Slide 4: Our Governance
OUR GOVERNANCE -_ Ms Sheena Jack Associate Prof Rob PI Mr Christian Bernecker Mr Brett Crowley Non-executive Executive Non-executive Company Secretary CEO Uscom CEO HCF Independent investor representative Mr Chao Xian (David) He Non-Executive Director China Medical Devices
Slide 5: Thank You
THANK YOU 2017 has been a year of results for Uscom as we continue to grow our business based on improving operational fundamentals, while consolidating our acquisitions and preparing 7 new products for market and new revenue streams for FY 2018 and beyond. The outstanding achievements of 2017 repre
Slide 6: Chairman's Report
CHAIRMAN’S REPORT OUR VISION Uscom is an innovator in cardiovascular and pulmonary medical devices, developing new non-invasive technologies to address the challenges of global disease and health care. OUR DRIVE Uscom is driven by a commercial ambition to become a leader in the global healthcare bus
Slide 7: aa Ss
5 _ aa Ss 3 Bp . YL 2 SEs 8 2 o 2 2 tT cE as ee—82% ®& 28 ¢ 5 2 6 = 2 2 5 og 3 $3 £3 g 3 8 & 9 © 2 8 ie) me} 2 OP § 2 > 3 xe) of 8 . 2 a £53388 E 5.0 8 8 § 62 8 s o © B38 225 362% 6 o &3 885 eu gas 8 9 2 3 Ba ow 2&8 8 8 8 fap 3 as sets $265 £5 g 6° g 5 3 g D
Slide 8: $4.0 $3.5 $3.0 • $2.5 • • $2.0 • $1.5 $1.0 $0.5 $0.0 2012
$4.0 $3.5 $3.0 • $2.5 • • $2.0 • $1.5 $1.0 $0.5 $0.0 2012 2013 2014 2015 2016 2017
Slide 9: Our Results: Total Cash Receipts
OUR RESULTS SAUD TOTAL CASH RECEIPTS ,$3,522,8 $2, sti a 646,782 ations 796 $1, TT 2013 2014 2015 2016 2017 2017 cash receipts increased by 20% to $3.5m, and at a CAGR of 36% over the last 4 years.
Slide 10: Our Results: Cash Consumption and After Tax Losses
OUR RESULTS CASH CONSUMPTION AND AFTER TAX LOSSES m2016 = 2017 1.92 1.80 1.29 $M AUD 0.99 CASH CONSUMPTION LOSS AFTER TAX Despite significant spend on product development, finalisation of acquisitions and regulatory payments, cash consumption decreased 30%, while loss after taxes decreased 6% in 201
Slide 11: 18.0 16.1 16.0 14.0 12.4 12.0 10.0 8.0 6.0 5.0 5.2 5.2 4.1 .0
18.0 16.1 16.0 14.0 12.4 12.0 10.0 8.0 6.0 5.0 5.2 5.2 4.1 4.0 2.0 0.0 2012 2013 2014 2015 2016 2017
Slide 12: Our Acquisitions
OUR ACQUISITIONS INVESTED IN TECHNOLOGY Uscom has invested in technology with two corporate acquisitions * central blood pressure monitoring * pulmonary function monitoring We have * integrated the companies * Redesigned, optimised + rebranded the new devices * prepared the products for market Launc
Slide 13: Development
DEVELOPMENT START
Slide 14: Concept
CONCEPT PATENT PROTOTYPE ESTABLISH QC
Slide 15: Validation
VALIDATION TESTING DESIGN MANUFACTURE
Slide 16: ISO Approval
ISO APPROVAL REGULATORY MARKETING
Slide 17: Finish: Revenue
FINISH REVENUE The process of turning IP into revenue is a long and expensive one, and while Uscom’s current accounts reflect revenue predominantly from the USCOM 1A, the BP+ and SpiroSonic devices have been prepared for global sales. This investment represents significant value for Uscom shareholde
Slide 18: Range
RANGE The USCOM 1A is a non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler ultrasound to detect abnormalities and guide treatment. The USCOM 1A has major applications in Paediatrics, Emergency, Intensive Care and Anaesthesia. The BP+ measures blood pressure
Slide 19: Product Launch
Slide 20: It's a Big Deal
IT’S A BIG DEAL + The BP+ is great science, and is: In board the International Space Station Used by UK servicemen and women to study pertension on Mount Everest in the Russian Space Programme drug evaluation trials with big ie Pi Xcransan Occurs in aprox 1:3 adults and » costs aprox $372B USD globa
Slide 21: Practice
PRACTICE — Rhythm Strip Data toad fie JI connec J “ Teemestanee | | | — ] Uscom BP+ uses patent protected | a Sia suprasystolic oscillometry to measure blood PEIN A ce ||emone tna pressure at the heart rather than at the arm, % 7 ~ © * mt as normal subsystolic blood pressure ee oe sa a Be Once rsa |
Slide 22: Science
SCIENCE Uscom BP+ at MONS University Belgium Uscom devices are based on precision science, and part of the development of Uscom products is the rigorous testing required to support their release. PS)
Slide 23: Lung Function
LUNG FUNCTION .] FOR EVERY BREATH YOU TAKE SpiroSonic )))
Slide 24: Devices
DEVICES OC ge, SOFTWARE Lung disease (asthma and COPD) occurs in approximately 20% of the population and is increasing SpiroSonic devices improve the diagnosis and treatment of lung disease Device redesign and rebranding complete New distribution in the US, China and SE Asia. Emerging eHealth applic
Slide 25: Our Science
OUR SCIENCE =) Research Publications Repository The feasibility of transcutaneous continuous wave Doppler ultrasound monitoring of cardiac output: Ultrasonic Cardiac Output Monitor (USCOM) Australian Government IP Australia European O}}} Patent Office Patents and publications prove the value of Usco
Slide 26: Regulation
REGULATION Regulatory approval is required for device sales into China (CFDA), Europe (CE), FDA (USA) and Australia (TGA). Uscom has a number of pending approvals in various jurisdictions over the next 12 mths which will allow sales into new markets USCOM 1A - CFDA, CE, FDA, TGA BP+— CFDA (submissio
Slide 27: Growth Strategy
GROWTH STRATEGY Expanded distribution Growth in scale * Global regulatory * Grow cap value to $200M * China market * Strategic partnerships Global CV and Pulmonary Devices Revenue growth + Leading science + Target - $10M, $20M, $50M * Multiple products * Sales and marketing support
Slide 28: Growth China
GROWTH CHINA STATE FUNDED GROWTH 1.38B population in31 provinces 20% PA China health growth UCM CEO on NSW Govt China Advisory 10 year history + China Govt partners CFDA BP+ and SpiroSonic initiated China revenue targets $20M % HEALTH SPEND 20 5.8 GROWTH m China ;USA 18 5.5 GDP SPEND 12 12 GDP GOAL
Slide 29: Growth Sales
GROWTH SALES @ GROWTH IN DISTRIBUTION AGREEMENTS Damien Linnett Global Sales Manager Appointed 2017 Bea Onal Marketing Coordinator Appointed 2017 Denise Pater 43 50 Global Distribution 36 Manager 23 a 2013 2014 2015 2016 2017 2018* Bev Jacobson Clinical Relations mROW China Manager
Slide 30: Why Now
e WHY NOW e After 5 years of investment Uscom is preparing for growth in 2018 founded on marketing of our 7 new products + New products — 1 to 8 (+700%) * New distribution — 53 to 75 (+32%) * New regulatory approvals (CE, FDA and CFDA) * More revenue — $3.5M to $10M, 20M, 50M + Incremental growth —
Slide 31: Uscom
Cd Uscom “Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”
Slide 32: Questions